Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. regulatory data
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • Older

Regulatory Data Articles & Analysis

21 news found

Advanced Bacterial Reverse Mutation Test (Ames) Service to Accelerate Medical Device Safety Assessment

Advanced Bacterial Reverse Mutation Test (Ames) Service to Accelerate Medical Device Safety Assessment

It is also a mandatory test when submitting registration or approval data to regulatory authorities for diverse chemicals, including pharmaceuticals and biocides. ...

BySTEMart


Protect your margins and ensure growth by making data-driven decisions

Protect your margins and ensure growth by making data-driven decisions

As the CEO of a feed or pet food company, you face daily challenges involving margin alignment, data accuracy, logistic challenges, and legislative compliance. Simultaneously, you're seeking opportunities for growth, increased profitability, maintaining a robust reputation, streamlining operations, and safeguarding your company's market standing amidst unstable market conditions. Each ...

ByBESTMIX


Comprehensive Gene Therapy Development Solutions to Further Boost Rare Disease Research

Comprehensive Gene Therapy Development Solutions to Further Boost Rare Disease Research

These achievements indicate a growing inclination among regulatory bodies to accept data on safety, efficacy, and durability for the endorsement of these treatments. ...

ByProtheragen


xCures partners with RenovoRx to assist patients in accessing RenovoRx’s TIGeR-PaC study

xCures partners with RenovoRx to assist patients in accessing RenovoRx’s TIGeR-PaC study

The platform prospectively generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials. ...

ByxCures


xCures Joins Big Names in Aetion’s New Initiative

xCures Joins Big Names in Aetion’s New Initiative

xCures, a Real-Time Regulatory Grade Clinical Data (RRC) platform, will be joining Aetion, a global real-world evidence software and analytics provider, and a group of leading diverse partners in Aetion’s launch of the Coalition for the Advancement of RWE through Randomized Controlled Trial Emulation (CARE) Initiative. ...

ByxCures


xCures presents clinical and translational research with two posters at the 2022 SNO Annual Meeting

xCures presents clinical and translational research with two posters at the 2022 SNO Annual Meeting

” The xCures platform generates Real-time, Regulatory-grade, Clinical data (RRC). It now includes data on over 1,000 brain cancer patients, permitting real-time insight into which treatments show the most promise across patient cohorts. Emerging data on investigational and off-label interventions will be presented for ...

ByxCures


Finally, cancer patients have real-time access to their medical records

Finally, cancer patients have real-time access to their medical records

The power lies in the underlying structuring of data” said Mika Newton, CEO of xCures. “Cancer is personal, and our ...

ByxCures


Detailed data from pivotal studies with aflibercept 8 mg demonstrate sustained improvements in visual acuity and anatomic measures with large majority of patients maintaining treatment intervals of 16 weeks at week 48

Detailed data from pivotal studies with aflibercept 8 mg demonstrate sustained improvements in visual acuity and anatomic measures with large majority of patients maintaining treatment intervals of 16 weeks at week 48

The full study results were presented during two late-breaking sessions at the 55th Annual Scientific Meeting of the Retina Society, USA. Bayer will submit these data to regulatory authorities outside of the USA. “These data show unprecedented durability of aflibercept 8 mg in patients living with age-related macular degeneration and ...

ByBayer AG


xCures and mProbe partner to help cancer patients determine optimal treatments

xCures and mProbe partner to help cancer patients determine optimal treatments

By integrating xCures’ rich real-world longitudinal clinical data with mProbe’s cancer proteomics panels, the two companies are working to expedite the discovery of predictive, diagnostic, and prognostic biomarkers for cancer. ...

ByxCures


Diamyd Medical joins international consortium in Type 1 Diabetes

Diamyd Medical joins international consortium in Type 1 Diabetes

The T1DC brings together diverse stakeholders from industry, academia and patient organizations to develop solutions to accelerate drug development for Type 1 Diabetes, including biomarker endpoints and model-informed drug development tools in close collaboration with regulatory agencies to enable easier and faster regulatory approval of new treatments. By ...

ByDiamyd Medical AB


xCures and Novocure partner to better understand quality of life in glioblastoma

xCures and Novocure partner to better understand quality of life in glioblastoma

“We are delighted to team up with Novocure and see our extensive real-world data from GBM patients applied towards developing a time series analysis of QOL in GBM,” said Mika Newton, CEO of xCures. ...

ByxCures


Intelligencia Raises $12M to Reduce the Risk of Clinical Research, Improve R&D Productivity, and Accelerate Scientific Breakthroughs

Intelligencia Raises $12M to Reduce the Risk of Clinical Research, Improve R&D Productivity, and Accelerate Scientific Breakthroughs

Its platform allows customers to: Accurately and efficiently assess the probability of success of pipeline drugs, with supporting rationale; Unlock the optimal trial design, with comprehensive benchmarks linked to clinical trial success; Identify and prioritize additional potential indications to explore for each asset; Guide business development decisions by quickly and objectively ...

Byintelligencia.ai


Axio Biosolutions raises $6 million in a Series B2 equity round led by TrueScale Capital

Axio Biosolutions raises $6 million in a Series B2 equity round led by TrueScale Capital

More recently, Axio has received regulatory clearance by the US FDA for Axiostat and the EU CE Mark to market Maxiocel for use in advanced wound care settings. ...

ByAxio Biosolutions Pvt Ltd


Ipsen receives positive CHMP opinion recommending Cabometyx® in combination with Opdivo® as first-line treatment for patients living with advanced renal cell carcinoma

Ipsen receives positive CHMP opinion recommending Cabometyx® in combination with Opdivo® as first-line treatment for patients living with advanced renal cell carcinoma

” The CHMP adopted the positive opinion based on results from the pivotal Phase III CheckMate -9ER trial, which demonstrated significant and clinically meaningful improvements in progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) compared to sunitinib, with consistent efficacy benefits observed across key subgroups of patients.1 Cabometyx® combined ...

ByIpsen Group


Woolsey Pharmaceuticals Emerges from Stealth Mode to Announce Patients Enrolled in Two New CNS Studies

Woolsey Pharmaceuticals Emerges from Stealth Mode to Announce Patients Enrolled in Two New CNS Studies

“Today’s announcement is an important milestone in bringing more than just hope to these patients and their loved ones.” Data readout in the study is anticipated in 2022. ABOUT PSP and CBS Progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) are rare neurodegenerative disorders associated with the accumulation of insoluble deposits of ...

ByWoolsey Pharmaceuticals, Inc.


Sterilis Wins 2017 Top Product of the Year Award for Green Medical Waste Disposal Device by Environmental Leader

Sterilis Wins 2017 Top Product of the Year Award for Green Medical Waste Disposal Device by Environmental Leader

Eliminates unnecessary paper documents currently needed with the current “haul and burn” approach through IoT-enabled software that automatically tracks and stores all required regulatory data in the cloud, where it can be accessed and monitored at any time. ...

BySterilis Solutions


Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer

Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer

Investigational compound LDK378 is a selective inhibitor of ALK[1], a target found in metastatic non-small cell lung cancer (NSCLC) Data show 60% overall response rate in 78 patients with ALK+ NSCLC taking LDK378 at 750 mg; will serve as basis for first filing in early 2014 FDA designated LDK378 as Breakthrough Therapy in March and a robust clinical development plan is ...

ByNovartis International AG


Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerability issues

Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerability issues

/www.w3.org/1999/xhtml">Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerability issues Novartis International AG / Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly ...

ByNovartis International AG


New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations

New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations

/www.w3.org/1999/xhtml">New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations Novartis International AG / New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations . ...

ByNovartis International AG


EPA to Expand Chemicals Testing for Endocrine Disruption

EPA to Expand Chemicals Testing for Endocrine Disruption

The list also includes pesticide active ingredients that are being evaluated under EPA’s registration review program to ensure they meet current scientific and regulatory standards. The data generated from the screens will provide robust and systematic scientific information to help EPA identify whether additional testing is necessary, or whether other ...

ByUS EPA - Environmental Protection Agency

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT